GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria

International Journal of Antimicrobial Agents

Volumn 18, Issue 1, 2001, Pages 29-35

  Deshpande, L M ^a,b   Gales, A C ^a   Jones, R N ^a  

^a UNIVERSITY OF IOWA   (United States)

^b MIKRON Group Inc   (United States)

Author keywords

Minocycline; Streptococci; Susceptibility

Indexed keywords

TIGECYCLINE;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM; CORRELATION FUNCTION; DRUG EFFECT; DRUG SCREENING; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0034900170     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00355-7     Document Type: Article

References (16)

1. Tetracyclines, molecular, and clinical aspects
2. Western Pacific Regional Gonococcal Antimicrobial Surveillance Program: Surveillance of antimicrobial susceptibility of Neisseria gonorrhoeae in the WHO Western pacific Region 1992-1994
3. The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory tract infections
4. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines
5. Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines
6. In vitro activities of two glycylcyclines
7. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade tet(M)- and tet(O)-mediated ribosomal protection
8. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae
9. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillence Program
10. Doxycycline and minocycline in the treatment of respiratory infections: A double-blind comparative clinical, microbiological and pharmacokinetic study
11. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci
12. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936
13. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152 288) against various gram-positive and gram-negative bacteria
14. Pharmacokinetics (PK), safety and tolerability og GAR-936, a novel glycylcycline antibiotic, in healthy subjects